WNK2 and fibrosarcoma: Sorafenib was reported to be able to directly inhibit tumor growth via inhibition of the rapidly accelerated fibrosarcoma/mitogen-activated protein kinase kinase/extracellular signal-regulated kinase signaling pathway.